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Vasculitis
AbstrAct
The European League Against Rheumatism 
recommendations for the management of antineutrophil 
cytoplasmic antibody-associated vasculitis have 
been recently published. Unique to recommendation 
development, they were also voted on by members of a 
learned society. This paper explores the wider validity of 
the recommendations among people who self-identify as 
clinicians caring for patients with vasculitis. In addition 
to the task force, a learned society (European Vasculitis 
Society—EUVAS) was invited, through online survey, 
to rate independently the strength of evidence of each 
recommendation to obtain an indication of the agreement 
among the final target audience and ultimate end-users 
of the recommendations. The survey took place in June 
2015. Of the 158 EUVAS members surveyed, there were 88 
responses (55.7%). There was a large degree of agreement 
in the voting patterns between EUVAS survey participants 
and task force members. Notable exceptions were lower 
grades for the recommendation of the use of rituximab 
for remission induction in patients with eosinophilic 
granulomatosis with polyangiitis and for methotrexate 
and mycophenolate mofetil as remission maintenance 
agents in patients with granulomatosis with polyangiitis/
microscopic polyangiitis by EUVAS members. These results 
are encouraging and suggest that the voting patterns of 
the task force are representative of the wider vasculitis 
community. We recommend future recommendations adopt 
this approach for data/expert-based treatment guidelines, 
especially for multisystem diseases.
IntroductIon
The European League Against Rheuma-
tism (EULAR) recommendations for the 
management of small-vessel and medi-
um-vessel vasculitides were recently updated, 
with a focus on antineutrophilic cytoplasmic 
antibody (ANCA)-associated vasculitis, and 
were coendorsed by the European Renal 
Association-European Dialysis and Transplant 
Association and European Vasculitis Society 
(EUVAS).1 The process for formation of such 
recommendations follows a standard meth-
odology.2 3 Since ANCA-associated vasculitis 
can present to physicians from a wide range 
of specialities, a task force was convened with 
representation from different subspecialisa-
tions.
Standard practice for voting on the recom-
mendations was followed but, for the first time, 
they were also voted on by members of a learnt 
society, which in this case was the EUVAS. 
EUVAS allows members to join the Society 
from around the world and as such is an open 
collaboration of physicians which aims to 
promote research and education in vasculitis.
Results from the Canadian Vasculitis 
Network revealed significant variations in prac-
tice highlighting the need for evidence-based 
management recommendations for ANCA-as-
sociated vasculitis.4 In addition, the publication 
of large collaborative trials, involving patients 
Key messages
 ► The results reveal a large degree of agreement in 
the voting patterns among EUVAS members who 
responded to the survey and the members of the 
task force.
 ► The generalisability of the findings is strengthened 
because the survey members derive from 29 
countries from around the world.
 ► One noted exception was the lower grade of 
recommendation for the use of rituximab in patients 
with EGPA amongst EUVAS survey responders.
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with ANCA-associated vasculitis, has advanced the evidence 
from which conclusions on treatment can be drawn.
This paper explores the wider validity of the recom-
mendations among people who self-identify as clinicians 
caring for patients with vasculitis.
Methods
developing the recommendations
Systematic review of several medical literature databases 
was used to identify clinical trials relevant for the purposes 
of developing the recommendations. Standardised 
procedures were followed in line with guidance from 
EULAR with evidence from clinical trials graded from A 
(highest—from at least one randomised controlled trial) 
to D (lowest—expert opinion).2 3 This evidence informed 
the development of statements. Finally, voting took place 
with individuals giving a strength of recommendation to 
the individual statements. Each task force member had a 
single independent vote for each statement. Strengths of 
recommendation are in part constrained by the category 
of evidence used to inform each statement.
desIgn
Wider validity exercise
In addition to the task force, a learnt society (EUVAS) was 
invited to rate independently the strength of evidence 
of each recommendation to obtain an indication of the 
agreement among the final target audience and ultimate 
end-users of the recommendations. Members of the task 
force whom were also members of EUVAS did not vote 
twice.
euVAs membership
EUVAS is an open collaboration of physicians interested 
in research and education in vasculitis and evolved from 
the European Vasculitis Study Group. EUVAS is a non-po-
litical, non-profit organisation with a primary objective to 
unite researchers and clinicians to promote the study and 
treatment of vasculitis. Five of the task force members 
form the current presidential council (DRJ, KWAW, 
IB, TH and AM). Membership to EUVAS is subject to 
approval by the presidential council after written appli-
cation. Ordinary membership is open to any clinician or 
scientist with a specific interest in the field of vasculitis. 
Associate membership is available to other individuals 
or institutions sharing an interest in vasculitis. There 
are 158 members of EUVAS from 28 different countries 
across Europe and across the globe.
sampling frame
The EUVAS membership was emailed and invited to take 
part in an online survey. Non-responders were sent a 
second invitation to encourage uptake.
Analysis
Tables of the spread of results, in this case the strength of 
recommendation, for each statement were constructed 
with the most popular (mode) presented first.
results
The survey took place in June 2015. The first email 
message was sent on 4 June 2015 with a link to an online 
survey. Two reminder emails were sent on 9 and 22 June. 
Of the 158 EUVAS members surveyed there were 88 
responses (55.7%). The members were from 29 coun-
tries, distributed across the continents of Asia, Europe, 
North America, Oceania and South America.
The most popular (mode) vote was considered the 
grade of recommendation with the corresponding 
median also presented (table 1).
The results reveal a high degree of concordance 
between the task force and EUVAS survey votes. Lower 
grades of recommendation by the EUVAS survey occurred 
for the use of rituximab (D vs C) in patients with eosino-
philic granulomatosis with polyangiitis (EGPA) suffering 
new-onset ANCA-associated vasculitis (AAV) and for 
maintenance therapy regimens using methotrexate or 
mycophenolate mofetil (B vs A). In non-organ, non-life 
threatening ANCA-associated vasculitis, no task force 
members voted grade A for use of methotrexate or 
mycophenolate in such situations, compared with 35% 
and 12% of the EUVAS group choosing these as options, 
respectively.
The task force also voted in a greater proportion for 
grade C than the EUVAS group for either methotrexate 
or mycophenolate for remission maintenance (35% 
vs 30% and 31%, respectively, for the EUVAS votes). 
Although both the task force and EUVAS voting patterns 
spread across the strengths of recommendation for meth-
otrexate and mycophenolate mofetil, there was much 
greater agreement for the use of azathioprine for remis-
sion maintenance therapy in AAV, reflecting favouring 
azathioprine as the agent of choice in such situations.
discussion
The results reveal a large degree of agreement in the 
voting patterns among EUVAS members who responded 
to the survey and the members of the task force. These 
results are encouraging and suggest that the voting 
patterns of the task force are representative of the wider 
vasculitis community. In addition, the generalisability 
of the findings is strengthened due to the distribution 
of countries from which the survey participants derive 
with representations from 29 countries around the 
world. However, the EUVAS group is likely to be a more 
research interested and active group compared with 
all clinicians who care for patients with AAV. We hope 
that the recommendations are adopted by all involved 
in the care of patients with AAV and draw attentions to 
the first statement. The purpose of surveying the EUVAS 
membership was to check that the task force did not hold 
widely different views.
There were key exceptions with lower grades of recom-
mendation for the use of rituximab in patients with 
EGPA among EUVAS survey participants. The reasons for 
this small discrepancy are unclear but may reflect EUVAS 
members' familiarity with the previous recommendations 
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Vasculitis
in which rituximab was assigned as grade 4 evidence.5 
The large rituximab in ANCA-associated vasculitis 
trial (RAVE) and rituximab versus cyclophosphamide in 
ANCA-associated vasculitis (RITUXVAS) trials did not 
include participants with EGPA and, generally, trials of 
agents used to treat patients with EGPA are of smaller 
size. In addition, most of the trials involving patients with 
EGPA included those with relapsing or refractory disease 
states. In addition, many disease-specific consequences of 
EGPA, such as asthma, are very glucocorticoid responsive 
making extrapolations from other medications used to 
treat other types of AAV difficult. This may have contrib-
uted to a lower grade being recommended by the EUVAS 
membership.
None of the task force considered a grade ‘A’ vote for 
mycophenolate mofetil, given appropriate situations, for 
remission induction. Indeed, the EULAR recommenda-
tions list a careful set of situations when these agents can 
be considered in non-organ, non-life-threatening presen-
tations of AAV.1
The survey revealed the task force voted grade A 
recommendation for methotrexate or mycophenolate 
mofetil as remission-induction agents, the strength of 
agreement was low (53%). The EUVAS survey revealed a 
grade B vote. However, a greater proportion of task force 
members voted for grade C in such scenarios compared 
with the EUVAS survey members (35% vs 15%). This may 
represent a loss in confidence in these two drugs in the 
practising community as compared with the results of the 
clinical trials that were interpreted by the task force.
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